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Dendritic spines are small actin-rich protrusions from neuronal dendrites that form the 
postsynaptic part of most excitatory synapses. Changes in the shape and size of dendritic 
spines correlate with the functional changes in excitatory synapses and are heavily 
dependent on the remodeling of the underlying actin cytoskeleton. Recent evidence 
implicates synapses at dendritic spines as important substrates of pathogenesis in 
neuropsychiatric disorders, including autism spectrum disorder (ASD). Although synaptic 
perturbations are not the only alterations relevant for these diseases, understanding the 
molecular underpinnings of the spine and synapse pathology may provide insight into their 
etiologies and could reveal new drug targets. In this review, we will discuss recent findings 
of defective actin regulation in dendritic spines associated with ASD. 
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embryonic day; FDR, false discovery rate; FMRP, fragile X mental retardation protein; FRAP, fluorescence recovery after 
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Diaphanous-related formin 2; mEPSC, miniature excitatory postsynaptic currents; mGluR, metabotropic glut amate 
receptors; mTOR, mammalian target of rapamycin; mTORC1, mTOR complex 1; MYH4/MyHC-IIb, myosin heavy chain 
IIb; MYO16, Myosin XVI; MYO9B, myosin IXb; NL, Neuroligin; NMD, Nonsense-mediated mRNA decay; NMDA(R), 
N-methyl-D-aspartate (receptor); NMJ, neuromuscular junction; OPHN1/ARHGAP41, Oligophrenin1/RhoGTPase 
activating protein 41; PAK, p21-activated kinase; PH, pleckstrin homology; PI3K, phosphatidylinositol 3-kinase; PSD, 
postsynaptic density; Rac1, Ras-related C3 botulinum toxin substrate 1; ROCK, Rho-associated coiled-coil containing 
protein kinase; SAM, sterile alpha motif; SAPAP, PSD-95-associated protein; SH3, Src homology 3; SHANK3, SH3 and 
multiple ankyrin repeat domains; sLTP, structural LTP; SR1-4, spectrin repeats; SRA1, specific Rac1-activated; STRN, 
striatin; STXBP5, syntaxin binding protein 5; SynGAP1, synaptic GTPase activating protein 1; SV, Synaptic vesicle; 
TADA, transmission and de novo association; TCGAP, TC10β/Cdc42-GAP; TSC, tuberous sclerosis complex; WRC, 
WAVE regulatory complex; Zn, zinc; α-Pix/Cool2, α-Pak interactive exchange factor/Cloned out of library 2. 
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1. Synaptic deficiency in autism spectrum disorder  
 
Autism spectrum disorder (ASD) comprises a range of neurological conditions that affect the 
ability of individuals to communicate and interact with others. ASD is characterized by impaired 
social interactions, communication deficits, and repetitive behaviors. ASD is typically diagnosed 
during the first 3 years of life, a period of extensive neurite formation, synaptogenesis and 
refinement1-4. Family and twin studies have revealed that ASD has a strong genetic component, 
with numerous genes being affected. In addition to mutations inherited from parents, many ASD-
associated mutations are rare protein disrupting de novo mutations that have arisen in the 
germline. Mutations can be copy-number variants (CNVs) or single-base-pair mutations5. By 
definition, CNVs are deleted or duplicated segments of DNA (>1,000 basepairs) that are thought 
to be involved in the pathogenesis of a wide range of human diseases, including ASD. At least six 
recurrent CNVs are among the most frequently identified genetic contributors to ASD6.  Overall, 
there seems to be an enrichment in ‘likely gene-disrupting’ mutations (LGDs; nonsense, 
frameshift and splice site mutations that often result in the production of truncated proteins) in 
individuals with ASD as compared to their healthy relatives or to other unaffected individuals5.  
Multiple ASD susceptibility genes converge on cellular pathways that intersect at the 
postsynaptic site of glutamatergic synapses7,8, the development and maturation of synaptic 
contacts9 or synaptic transmission10. The majority of excitatory glutamatergic synapses are 
located in small dendritic protrusions known as spines. The formation, maturation and 
elimination of dendritic spines lie at the core of synaptic transmission and memory formation11,12. 
Many of the ASD risk genes encode synaptic scaffolding proteins, receptors, cell adhesion 
molecules or proteins that control actin cytoskeleton dynamics, all of which directly affect 
synaptic strength and number and, ultimately, neuronal connectivity in the brain. In addition, 
ASD risk genes encode proteins that are involved in chromatin remodeling, transcription, and 
protein synthesis or degradation, all of which can act as upstream controllers of the expression 
levels of synaptic proteins. Changes in any of these proteins can affect dendritic spine density in 
the brain. When deleterious mutations occur, an individual’s risk for ASD is further affected by 
how well the defects of a single mutation can be compensated in the brain7.  
Increased spine density has been observed in the frontal, temporal, and parietal lobes of human 
ASD brains13 and recent studies indicate a defect in dendritic spine pruning from 13-18 years of 
age14. Tang et al. (2014) proposed that this pruning deficit may contribute to abnormalities in the 
cognitive functions that humans acquire in their late childhood, teenage, or early adult years, 
including the acquisition of executive skills such as reasoning, motivation, judgment, language, 
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and abstract thinking15. Many children diagnosed with ASD reach adolescence and adulthood 
with functional disability in these skills, in addition to social and communication deficits16. 
Although human ASD studies have reported increased dendritic spine density13,14, only a few 
genetic ASD animal models display this effect, making it unclear whether the increased spine 
density causes ASD-like behavior or whether any change in the number or function of synapse 
leads to atypical brain connectivity and symptoms of ASD7.  
One of the mouse models that does mimic the spine-pruning defect seen in humans has a 
constitutively overactive mammalian target of rapamycin (mTOR)14. In this model, the 
mechanism behind the defective spine pruning is an autophagy deficiency in synapses. 
Autophagy is an evolutionarily conserved cellular process that provides nutrients during 
starvation and eliminates defective proteins and organelles via lysosomal degradation. 
Hyperactive mTOR inhibits autophagy at an early step in autophagosome formation17. Inhibition 
of neuronal autophagy produces ASD-like inhibition of normal developmental spine depletion, 
without affecting the rate of spine formation, leading to increased spine density and ASD-like 
behaviors14. This model offers one mechanism underlying increased spine density and ASD-type 
behavior, but considering the heterogeneity of ASD genetics, it is likely that other mechanisms 
affecting spine pruning are defective in different ASD patients. Interestingly, it has been reported 
that mutations of five autism-risk genes with diversified molecular functions all lead to a similar 
ASD phenotype of behavioral inflexibility, indicated by impaired reversal-learning in 
Drosophila18. These reversal-learning defects result from an inability to activate Ras-related C3 
botulinum toxin substrate 1 (Rac1)-dependent forgetting18. In mammalian neurons, Rac1 affects 
spine structure, regulates synaptic plasticity in the hippocampus and is required for proper 
hippocampus-dependent spatial learning19,20. Active Rac1, when targeted to potentiated spines, is 
able to deplete targeted synapses21. Rac1 is one of the main regulators of the actin cytoskeleton 
and, therefore, one of the possible mechanisms underlying the defective spine pruning is deficient 
regulation of the synaptic actin cytoskeleton. It is also possible that spine pruning is normal, but 
spine formation is overactive, leading to increased spine density.  
Although ASD is considered one of the most heritable neurodevelopmental disorders22,23 and 
majority of the research on ASD has focused on the genetics of the disorders24,25, single causative 
gene anomalies account for only a small proportion of ASD cases26,27. To date, inheritance of 
multiple gene variants, rare de novo single gene mutations and copy number variants have been 
proposed to be liable for ASD. In addition, a multitude of environmental risk factors have been 
proposed to contribute to the development of ASD26. Prenatal environmental conditions, such as 
maternal infections during pregnancy, have been linked to social communication difficulties in 
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children with ASD-associated CNVs28. Other environmental factors that have been proposed to 
interact with risk genes include preterm birth, folate deficiency, and exposure to certain toxins28. 
One of these risk factors is lead exposure, which can cause dose-dependent changes in DNA 
methylation29, and among the hypomethylated genes caused by lead exposure, some affect actin 
cytoskeleton30.  
Genes associated with autism are listed at publicly accessible websites SFARI Gene 
(https://gene.sfari.org/database/human-gene/) and AutismKB (http://autismkb.cbi.pku.edu.cn/ 
index.php). In this review, we evaluate the current literature from SFARI listed genes, which 
encode proteins that regulate actin dynamics and have been linked with autism (Table I and II). 
The review aims to discuss the current literature to unravel whether the actin regulators encoded 
by ASD-associated genes regulate synaptic structure and function, and if yes, how? Additionally, 
the review aims to identify any common pathways on synaptic or actin regulation among these 
ASD-associated actin regulators. 
 
 
2. The role of actin cytoskeleton and actin binding proteins on the imbalanced spine 
formation and plasticity in ASD 
 
Although a wide range of autism-associated genes has been identified, it is becoming 
increasingly evident that many of these genes converge into common cellular pathways 
associated with neurite outgrowth, synaptogenesis, synaptic plasticity and spine stability, which 
together regulate the structural stability of neurons. Actin is the building block of cells and 
regulates the shape and density of dendritic spines31. Perturbing actin cytoskeleton and its 
regulators can lead to an imbalance in cytoskeleton dynamics, which in turn, can cause alterations 
in dendritic spine size, shape and number, as well as neural arborization. The correct morphology 
of synapses is key to the formation of functional neuronal circuitry and deficits in the structural 
stability of dendritic spines have been reported in several neurological disorders, including fragile 
X syndrome (FXS)32, schizophrenia33,34 and autism35.  
 
2.1 Regulation of F-actin polymerization and depolymerization  
 
The dynamic remodeling of the actin cytoskeleton is a critical part of most cellular activities, and 
the transition between two forms of actin, monomeric globular (G)-actin and filamentous (F)-
actin, is tightly regulated in time and space by a large number of signaling, scaffolding and actin-
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binding proteins. Most of these proteins integrate actin binding, protein-protein interaction, 
membrane binding, and signaling domains. In response to extracellular signals, often mediated by 
Rho family GTPases, actin-binding proteins control the cellular actin cytoskeleton by regulating 
actin filament nucleation, elongation (=polymerization) and treadmilling, maintenance, severing, 
capping, and depolymerization.  
 
Cortactin-binding protein 2 (CTTNBP2) is highly expressed in dendritic spines where it locally 
interacts with proteins to control the formation and maintenance of the spines. The dendritic spine 
head typically contains a dense network of short, cross-linked, branched F-actin31, and CTTNBP2 
has been shown to regulate the mobility and distribution of cortactin which, in turn, controls 
dendritic spine morphogenesis via F-actin branching and stabilization36-38 (Figure 1). Cortactin 
expression supression39 and CTTNBP2 knockdown in neurons37 reduce the spine density39, 
indicating their importance for the formation and maintenance of the spines. Cortactin acts 
downstream of CTTNBP2 in spine morphogenesis, as the defects caused by CTTNBP2 
knockdown can be rescued by cortactin overexpression but not by overexpressing a CTTNBP2 
mutant protein that cannot bind cortactin37. Furthermore, CTTNBP2 oligomerization has been 
shown to promote dendritic arborization through microtubule bundling40. Several mutations of 
CTTNBP2 gene have been reported in ASD cases41-43, indicating the importance of correct 
dendritic spine structure and density for proper brain function. In addition, CTTNBP2 is also 
found to regulate the synaptic distribution of striatin 4 (STRN4) and zinedin, which are the 
regulatory B subunits of protein phosphatase 2A (PP2A), suggesting that CTTNBP2 targets the 
PP2A complex to dendritic spines, and together with cortactin regulate spine morphogenesis and 
synaptic signaling36,44. The involvement of these proteins in autism has been speculated45, and in 
support of this, the human STRN4 gene is located in chromosome 19q13.32, which is the locus 
for a reported deletion in ASD46.  
 
Cytoplasmic FMRP-interacting protein 1 (CYFIP1) engages in two distinct molecular 
complexes where it coordinates mRNA translation and actin cytoskeleton remodeling to ensure 
correct dendritic spine formation47. CYFIP1, also known as specific Rac1-activated (SRA1) 
protein48, interacts with fragile X mental retardation protein (FMRP)49-53, which regulates the 
dendritic targeting of mRNAs54 and controls mRNA decay and protein synthesis in the neuronal 
soma and at spines50. FMRP tethers specific mRNAs to CYFIP1, which then sequesters the cap-
binding protein eIF4E and mediates translational repression55 (Figure 1). Translation of target 
mRNAs, such as Arc/Arg3.1 which are important for synaptic structure and function47, is 
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triggered when group I metabotropic glutamate receptors (mGluRs) or the brain-derived 
neurotrophic factor (BDNF)/NT-3 growth factor receptor (TrkB) are activated and CYFIP1 is 
released from eIF4E and shifted to the WAVE regulatory complex (WRC)55.  The equilibrium of 
the two complexes is controlled by small GTPase Rac1, which alters the conformation of 
CYFIP147,48,53. The heteropentameric WRC, consisting of the proteins WAVE1/2/3, ABI1/2, 
NCKAP1, HPSC300 and CYFIP1 or CYFIP2, is one of the critical modulators of actin filament 
reorganization in neurons56. The WRC triggers N-WASP-dependent activation of actin-related 
protein (Arp)-2/3-dependent actin nucleation57,58, which controls actin filament rearrangements 
connected to dendritic spine formation, retraction, motility, structure and stability59. Disturbing 
WRC function by genetic ablation of the WRC components therefore alters dendritic spine 
structure and affects excitability60-62. CYFIP1 is highly enriched at synapses and its expression 
level is important for correct dendritic arborization and neuronal morphological complexity. 
Overexpression of CYFIP1 in hippocampal neurons in vitro has been shown to cause altered 
dendritic spine morphology and lead to an increase in dendritic length and complexity63. Neurons 
derived from Cyfip1+/− animals, on the other hand, show an increased mobility of F-actin, 
reduced dendritic complexity and an increase in immature dendritic spines both in vitro and in 
vivo63. Cyfip1 and Cyfip2 are members of a highly conserved gene family52, and dysregulation of 
Cyfip1 expression levels leads to pathological changes in neuronal maturation and connectivity, 
both of which may contribute to the development of the neurological symptoms observed in ASD 
and schizophrenia63. A CNV in the 15q11.2 region of the human genome has been implicated in 
several neurological and neuropsychiatric conditions64-70 and a CYFIP1 CNV within 15q11.2 has 
been linked to ASD71, with an upregulation of CYFIP1 mRNA being demonstrated in genome-
wide expression profiling of ASD patients with 15q11–q13 duplication72. A rare CYFIP1 deletion 
has also been reported in a patient with a mild intellectual disability and a pervasive 
developmental disorder not otherwise specified71. CYFIP1 therefore represents a link between 
Rac1, the WAVE complex and FMRP, orchestrating two molecular pathways, translational 
control and actin polymerization, both of which are necessary for correct spinogenesis in 
neurons.  
ASD shares common brain circuit alterations and brain abnormalities, such as defects in synaptic 
transmission and dendritic spine morphology with intellectual disability e.g. FXS. In contrast to 
the wide heterogeneity of autism-associated genes, FXS is caused by the silencing of FMR-1 that 
codes for FMRP73. Although most cases of autism are not associated with FXS, the prevalence of 
autism in FXS is estimated to range from 5% to 60%74. FXS is the most common form of 
inherited intellectual disability, with the patients displaying dendritic spine defects75, 
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neurodevelopmental delay, and autistic-like characteristics76. FXS is a frequent monogenic cause 
of ASD74,76-78 and the behavioral overlap between autism and FXS patients suggests overlapping 
neuronal network mechanisms that increase susceptibility to ASD. The regulatory function of 
CYFIP1 in the context of FMRP- and WAVE-containing complexes and subsequent actin 
remodeling may explain the convergence of these two neurodevelopmental disorders. 
 
The diaphanous homolog 3 (DIAPH3) gene encodes the actin polymerization factor formin 
DRF3 (called mDia2 in mice). The formin family of proteins are known to polymerize straight, 
non-branched actin filaments79 (Figure 1). The small GTPase Rif, and its downstream effector 
mDia2, play a central role in regulating actin dynamics during dendritic filopodia elongation80. 
Depletion of mDia2 in cultured neurons resulted in shorter dendritic protrusions whereas over-
expression of active mDia2 led to long dendritic filopodia80. In addition to the regulation of spine 
morphogenesis, mDia2/DFR3 has a significant role in neurite extension81. 
A maternally inherited deletion and a paternally inherited functional single-nucleotide mutation 
in a highly-conserved nucleotide sequence of DIAPH3 have been reported in a normally 
intelligent patient with an autistic disorder, suggesting a homozygous loss of function in the 
DRF382. Rare genomic alterations in DIAPH3 have also been found in rare epileptic 
encephalopathies such as the continuous spike and waves during slow-wave sleep (CSWSS) 
syndrome and Landau-Kleffner syndrome (LKS)83. CSWSS and LKS patients can display 
behavioral manifestations that overlap those of ASD, implying a possible clinical link between 
the disorders83.  
 
Gelsolin (GSN) is a Ca2+-sensitive actin binding protein that is widely expressed throughout the 
adult mammalian brain. Gelsolin severs F-actin filaments by breaking the noncovalent bonds 
between actin monomers, and remains bound to the barbed ends of the filaments, inhibiting their 
extension84,85 (Figure 1).  Dendritic spines are motile structures that contain high concentrations 
of filamentous actin, and based on a fluorescence recovery after photobleaching (FRAP) 
experiment in hippocampal neurons, the great majority (around 85%) of the F-actin in the spines 
is dynamic86. The induction of long-term depression (LTD) has been shown to decrease the 
amount of dynamic actin in the spine, increasing the portion of stable F-actin86, the effect of 
which is impaired in Gsn-deficient mice86. This actin stabilization was shown to depend on Ca2+ 
influx86 and N-methyl-D-aspartate (NMDA) receptors86, which have previously been implicated 
in actin-signaling pathways in spines87. Gelsolin has been shown to have a role in neurogenesis: 
In the adult mammalian brain, neurons are continually generated in two distinct brain regions, the 
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dentate gyrus, where newly generated cells remain relatively static88, and the olfactory bulb, 
where migratory neuroblasts differentiate into interneurons89. The migration of newly generated 
neuroblasts into the olfactory bulb has been shown to decrease in Gsn−/− mice while the 
neurogenesis in the hippocampus increases90. Moreover, neural progenitor cells derived 
from Gsn−/− mice show reduced migratory capacity in vitro whereas neuronal differentiation and 
proliferation kinetics are not affected90.  
A de novo substitution variant in an intron of the GSN gene has been identified in a proband with 
Asperger syndrome from a deep resequencing dataset generated from a cohort of ASD and 
schizophrenia cases91. Further support on the involvement of gelsolin and dendritic spine 
morphology on ASD comes from a study on a neurological disorder called tuberous sclerosis 
complex (TSC). 30%–50% of TSC patients are affected by ASD92-95. The stress-induced 
activating transcription factor-3 (Atf3)-gelsolin cascade, following mTOR hyperactivation, was 
shown to underlie dendritic spine deficits in mice with loss-of-function mutations in tuberous 
sclerosis complex 1 (Tsc1) or Tsc2 genes96. 
 
2.2 Actin cross-linking proteins 
 
When a spine matures, a pool of F-actin is stabilized to form a relatively stable core97. This core 
actin is a result the action of F-actin cross-linking proteins, which connect the actin filaments 
together into a thicker actin bundle. These bundles can be either contractile or non-contractile, 
depending on whether they contain active myosin II. In addition to creating bundles, actin cross-
linkers often protect filaments from depolymerization or at least slow down the depolymerization 
rate. The actin cross-linkers which have been shown to play a role in morphological dendritic 
spine maturation are non-muscle myosin IIb97-99, calcium calmodulin kinase II  (CaMKII100, 
drebrin101-103, α-actinin-2104 and α-actinin-4105. In addition to these functions, actin cross-linkers 
often provide a scaffolding platform for protein interaction and many of them link synaptic 
receptors to the actin cytoskeleton. From these proteins, de novo mutations in α-actinin-4 and 
myosin IIb, have been reported in ASD106.  However, myosin IIb is not listed in SFARI and is 
therefore excluded from this review. 
 
Alpha(α)-Actinin-4 (ACTN4) is a member of the evolutionarily conserved family of α-actinins 
(α-actinin-1-4)107. All isoforms, except α-actinin-3, are found in the brain108, with α-actinin-4 
being expressed in the hippocampus, cortex, and cerebellum105. The full-length human α-actinin-
4 protein is divided into three functional subdomains: The N-terminal actin-binding domain, 
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which is composed of two calponin homology domains (CH1 and CH2), the C-terminal EF-hands 
(helix-loop-helix structural motif), and the central rod domain, which is composed of four 
spectrin repeats (SR1-SR4)109,110. Antiparallel dimerization of the molecules results in the 
formation of a dimer with an actin-binding domain located at both ends. Dimer formation is 
required for its normal function as a cross-linker of the actin cytoskeleton111 (Figure 2). In 
addition to binding to actin filaments, actinins interact with membrane receptors112-115, signaling 
and adhesion proteins, and phosphoinositides116, and their positioning at the interface between the 
plasma membrane and cortical actin meshwork may afford a functional link between receptor 
activation and modification of the actin cytoskeleton. α-Actinin-4 is enriched at excitatory 
synapses, it colocalizes with group 1 metabotropic glutamate receptors (mGluRs)105 and it binds 
CaMKII117. It regulates dendritic protrusion dynamics and morphogenesis and is required for the 
mGluR-induced dynamic remodeling of dendritic protrusions105. Activation of group 1 mGluRs 
leads to CaMKII phosphorylation and weakening of the α-actinin-4/CaMKII interaction. 
However, synaptic transmission is not significantly affected by down-regulation of α-actinin-4, 
indicating that synapses are still formed normally105.  
The ACTN4 gene was originally identified as an ASD candidate gene based on its enrichment in 
an autism-associated protein interaction module (=synaptic transmission); sequencing of post-
mortem brain tissue from 25 ASD cases resulted in the identification of significant non-
synonymous variants in this gene10. Furthermore, a de novo missense mutation in the ACTN4 
gene was found by whole exome sequencing118. Iossifov and colleagues (2014) found a missense 
M554V (methionine to valine) point mutation in SR3. Spectrin repeats form a platform for 
protein-protein interactions but experimental analysis is needed to validate the effect of this 
mutation. 
 
CaMKII  (CAMK2A) and CaMKII  are central regulators of synaptic plasticity. Compared to 
CaMKII , CaMKII localizes poorly to dendritic spines119, and it was thought that it did not bind 
actin but was recruited to spines through oligomerization with CaMKII100. However, another 
study used single-molecule tracking to show that CamKII does in fact bind to actin, although 
this binding was threefold weaker than that observed for CaMKIIβ120.  
A de novo missense variant (E183V, glutamate to valine) in the CAMK2A gene was identified in 
an ASD proband from the Simons Simplex Collection118. Additional functional characterization 
demonstrated that this de novo E183V mutation in the CaMKII catalytic domain decreases both 
CaMKII substrate phosphorylation and regulatory autophosphorylation on Thr286, and that the 
mutated kinase acts in a dominant-negative manner to reduce CaMKII-wildtype 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
autophosphorylation121. The mutation also reduced the protein stability and the number of 
dendritic spines, induced synaptic deficits and caused ASD-related behavioral alterations in 
mice121. Furthermore, E183V mutation reduced CaMKII binding to established ASD-linked 
proteins, such as Shank3 and subunits of L-type calcium channels and NMDA receptors, and 
increased CaMKII turnover in intact cells121. This example demonstrates how a seemingly non-
damaging single amino acid change can lead to multiple defects in protein function and several 
cellular and behavioral defects.  
 
The VIL 1 gene encodes a Villin 1 protein. Villins are Ca2+-regulated actin-binding proteins, 
which function in the cytoplasm by severing, capping, nucleating, and bundling actin filaments122 
(Figure 2). Villins are best known for their role in the assembly and maintenance of microvilli in 
polarized epithelial cells. Villin also has a regulated nuclear localization and its function in the 
nucleus may play an important role in tissue homeostasis. The VIL1 gene was identified in an 
ASD whole-exome sequencing study and subsequent TADA (transmission and de novo 
association) analysis as a gene strongly enriched for variants likely to affect ASD risk43. 
However, the expression and function of Villin 1 in neurons is currently unknown. 
 
2.3 Actin-binding myosin motors  
 
Myosins are a large family of ATP-dependent motor proteins that use actin filaments as their 
tracks. There are 18 different myosin classes currently known. Some myosins are expressed only 
in muscles, whereas others are expressed solely in non-muscle cells. The best-known function of 
myosins is their role in muscle contraction. However, they are also involved in cargo transport, 
actin filament contraction in non-muscle cells, stereocilia formation and cell division. Synapses 
undergo continuous molecular and structural changes and myosins contribute to these processes 
by mediating actin cytoskeleton rearrangement and cargo transport123. In dendritic spines, non-
muscle myosin IIb drives actin cytoskeleton dynamics in response to synaptic stimulation97,124. 
Myosin Va plays a critical role in spine and synapse development by trafficking the α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors into dendritic spines125. 
Mutations in MYO5A cause severe neurological defects, including intellectual disability and 
seizures126,127. 
 
Myosin XVI (MYO16) is an unconventional actin-based molecular motor with ATPase activity 
(Figure 3). The expression and phosphorylation of myosin XVI (Myr8 or NYAP) in the cortex 
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and cerebellum peak during early development, having a role in regulating neuronal migration 
and neurite extension128. Myosin XVI binds directly to F-actin and also regulates stress fiber 
remodeling in fibroblasts and neurite outgrowth in neurons via its interaction with 
phosphatidylinositol 3-kinase (PI3K) and the WAVE complex129. Genetic association between 
the MYO16 gene and autism has been found in two large cohorts (AGRE and ACC) of European 
ancestry and replicated in two other major cohorts (CAP and CART)130, as well as in other 
studies131-134.  
 
The full-length human myosin IXb (MYO9B) protein contains a motor head domain, four IQ 
calmodulin-binding motifs in the neck area and a Zn2+-binding domain and RhoGAP domain in 
the tail135. This motorized RhoGAP is mostly studied in cancer cell lines, where it localizes to the 
sites of actin polymerization136 (Figure 3). However, myosin IXb is also expressed in the central 
nervous system (CNS) and in cortical neurons, where it has been shown to control RhoA activity, 
thereby regulating the growth and branching of dendritic processes137. Knockdown of myosin 
IXb in cultured cortical neurons or in the developing cortex results in decreased dendrite length 
and number137. The role of myosin IXb in dendritic spine morphogenesis is unknown but as 
RhoA seems to inhibit dendritic spine growth138, a protein inhibiting RhoA should have a positive 
effect on spine formation and maturation. Mutations in the MYO9B gene are associated with 
autoimmune diseases such as celiac disease139 as well as schizophrenia140. The MYO9B gene was 
also identified in an ASD whole-exome sequencing study and subsequent TADA analysis as a 
gene strongly enriched for variants likely to affect ASD risk43. Whole exome sequencing applied 
to families with an ASD child revealed de novo missense mutations in MYO9B leading to an 
amino acid change in the RhoGAP domain118.  
 
Although the myosin heavy chain IIb isoform (MyHC-IIb) (MYH4) is the predominant motor 
protein in most skeletal muscles of rats and mice, the mRNA for this isoform is only expressed in 
a very small subset of specialized muscles in adult large mammals, including humans141. MyHC-
IIb expression is typically associated with high forces of contraction combined with rapid 
contractile characteristics, and it has been suggested that these contractile characteristics may be 
incompatible with the biomechanical constraints of larger muscles142. Considering that its 
predominant role is in skeletal muscles, it is rather surprising that two families with children 
having ASD showed a loss of MYH4 inherited from a healthy mother143. However, the Allen 
brain atlas shows relatively strong expression of MYH4 gene throughout the brain, including in 
pyramidal neurons in the hippocampus and Purkinje cells in the cerebellum. MyHC-IIb null mice 
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are viable, probably due to compensation by other skeletal muscle fast isoforms144. Further 
studies are required to elucidate how this muscle myosin contributes to neuronal function.  
 
2.4 Cohesive proteins, linking F-actin to other support proteins and extracellular matrix 
 
The distinctive shape of a cell is dependent not only on the organization of F-actin but also on 
proteins that connect the filaments to the membrane. A subset of actin-binding proteins, discussed 
below, provides a link between the intracellular actin cytoskeleton and the extracellular matrix, 
and functions to maintain the integrity of the plasma membrane.  
 
Dystrophin (DMD) is best known as a gene affected in Duchenne muscular dystrophy. This X-
linked recessive degenerative neuromuscular disorder is often associated with CNS disorders 
such as intellectual disability, learning deficits, particularly in relation to language, and ASD145-
147. Large out-of-frame gene deletions or duplications of the DMD gene account for two thirds of 
the mutations in these patients, and gene microdeletions, insertions, or point mutations occur in 
the remaining third148. Through two CH domains in tandem at its N-termini, dystrophin provides 
a link between the intracellular actin cytoskeleton and the extracellular matrix (laminin), which 
stabilizes the plasma membrane. Dystrophin is most abundant in skeletal and cardiac muscle149. 
The only non-muscle tissue that expresses substantial quantities of dystrophin is the brain149, 
where it is found at approximately 10% of the level found in skeletal muscle. The DMD gene 
encodes at least seven distinct proteins. Although it was initially thought that full-length 
dystrophin was associated with excitatory synapses150, several independent studies indicate that 
the main function of dystrophin is the regulation of inhibitory synapses151 (Figure 4).  
 
Utrophin (UTRN) is the closest homolog of dystrophin and functions in a similar way. Studies in 
utrophin-deficient mice have revealed a reduction in the number of postsynaptic-membrane folds 
and acetylcholine receptors at the neuromuscular junction (NMJ)152,153 (Figure 4). These mice are 
viable and show no sign of muscular weakness and no compensation by dystrophin expression. 
The pattern of utrophin expression around the soma of neurons is different from the punctate 
expression of dystrophin in synaptic structures, suggesting that utrophin provides structural 
support for neuronal membranes, whereas dystrophin is a component of inhibitory synapses154. 
Interestingly, high utrophin immunoreactivity was reported several weeks after the induction of 
morphogenic changes in granule cells of the dentate gyrus in an experimental model of temporal 
lobe epilepsy, suggesting that utrophin contributes to protect CNS neurons against pathological 
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insults via long-term structural stabilization of their membranes154. Utrophin was originally 
identified as an ASD candidate based on its enrichment in an autism-associated protein 
interaction module. Sequencing of post-mortem brain tissue from 25 ASD cases resulted in the 
identification of significant non-synonymous variants in this gene, confirming the involvement of 
this module in autism; this finding was further validated by exome sequencing of an independent 
cohort of 505 ASD cases and 491 controls10. 
 
2.5 Synaptic scaffolding proteins and synaptic vesicle regulators affecting the actin 
cytoskeleton  
 
Postsynaptic scaffolding proteins cluster cell adhesion proteins, ion channels, neurotransmitter 
receptors and cytoskeletal regulators to confined synaptic sites, supporting the connection 
between synaptic structure and signaling. Scaffolding proteins are highly abundant in the 
postsynaptic density (PSD), in terms of both protein copy numbers and the distinct protein 
types155,156. The role of these scaffolding proteins is connected to neuronal function, and when 
disrupted, neuronal morphology and synaptic plasticity are subsequently affected, contributing to 
the etiology of diverse human psychiatric disorders such as schizophrenia, ASD, and obsessive-
compulsive spectrum disorders157.  
 
The SH3 and multiple ankyrin repeat domains (SHANK) proteins 1-3, coded by the 
SHANK1-3 genes, constitute a scaffolding protein family that is highly enriched in the PSD158. 
SHANKs (also known as ProSAPs) contain several discrete domains including ankyrin (ANK) 
repeat domains, Src homology (SH) 3 and PDZ domains, a proline-rich region, and a sterile alpha 
motif (SAM) domain159,160. These protein interaction domains enable SHANK proteins to interact 
with a multitude of postsynaptic proteins, linking SHANK proteins to ionotropic glutamate 
receptors via PSD-95 and PSD-95-associated protein (SAPAP) interactions160, intracellular Ca2+ 
signaling via HOMER interactions161, and, actin cytoskeleton regulation via cortactin160, α-
fodrin162, Rac1163 and actin binding protein 1 (Abp1)164 interactions, among others (Figure 
5). Cortactin, Abi-1 (Abelson interacting protein 1), and IRSp53 (insulin receptor substrate p53) 
bind to the SHANK3 proline-rich domain. Abi-1 regulates the actin cytoskeleton via the Arp2/3 
complex, and its knockdown increases dendritic branching and the number of immature spines, 
but reduces synapse density165. Fodrin stabilizes actin filaments and serves as a calmodulin-
binding protein166, linking SHANK proteins indirectly to Ca2+ sensing. Different point mutations 
identified in the ANK domain of SHANK proteins prevent alpha-fodrin and SHARPIN167 
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binding. Loss of fodrin binding may lead to labile actin filaments leading to alterations in spine 
density and spine maturation168. In non-neuronal cells SHARPIN is known to inhibit integrin 
activation169. Interesting new evidence from non-neuronal cells show that SHANKS can also 
inhibit integrin activation. However, this integrin activation inhibition was not mediated through 
SHARPIN but by sequestering active Rap1 and R-Ras from the plasma membrane170.  
Furthermore, autism-linked mutations (R12C, arginine to cysteine; L68P, leucine to 
proline)168,171,172 in SHANK3 impaired its integrin inhibitory function in non-neuronal cells170 
prompting a new intriguing proposal that at least some of the SHANK ASD-associated mutations 
alter the integrin activation in neurons.  
In general, SHANK1 promotes dendritic spine head enlargement, and SHANK2 and 3 promote 
dendritic spine formation, with SHANK3 also inhibiting dendritic spine arborization by binding 
to Densin-180173-177. Shank3 knockout mice suffer from a loss of cortical actin filaments, in 
association with reduced Rac1/p21-activated kinase (PAK) activity together with increased 
activity of cofilin178. Overexpression of Shank3 has been found to enhance actin 
polymerization168 and increase F-actin levels179. The SHANK proteins can regulate Rac1 activity 
through RhoGEF beta-PIX163 and RhoGAP RICH2180. The altered synaptic actin filament 
regulation could be connected to the loss of synaptic NMDA receptors observed in these animals, 
which is proposed to contribute to their autism-like behavior.  
Shank1-/- mice provide an animal model for human shankopathies, displaying alterations in 
synaptic protein composition and impairments in dendritic spine morphology, with the spines 
being thinner and smaller, and the spine number decreased175,181,182. Shank2-/- mice, which exhibit 
almost all the core features of ASD such as increased stereotypic behavior, impairment in social 
interaction, hyperactivity and anxiety show a similar reduction in the number of dendritic spines 
and a decrease basal synaptic transmission with depletion of NMDA receptors183. Several mouse 
models have been generated to investigate the role of Shank3 and its splice variants in ASD. A 
complete knockout of Shank3 in mice resulted in defective corticostriatal circuitry and fewer and 
thinner PSDs184. The autistic mouse model also showed impaired function of striatal synapses 
and abnormalities in brain morphology184.  
CNVs and truncating mutations of SHANKs have been identified in almost 1% of ASD 
patients185, making the SHANK family of proteins central to the pathophysiology of autism. 
Altered gene function of all SHANKs has been associated with syndromic and idiopathic ASD186. 
Shank mutations have very high penetrance at the phenotypic level, and any form of SHANK3 
haploinsufficiency is sufficient to cause behavioral changes187. Given that the SHANK proteins 
are modulators of dendritic spine morphogenesis, it is plausible that related mutations or 
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deletions lead to alterations in spine homeostasis. In support of this, deficiency or autism-related 
mutations of Shank3, the most prevalent of the three, result in altered cortactin, Abp1, cofilin and 
Rac1 expression or activity, increased integrin activation and a reduction in dendritic spines and 
synaptic dystrophy168,170,178,188. Furthermore, rare de novo CNVs, deletions and duplications in 
genes encoding SHANK interacting proteins such as Disk large-associated protein 2 (DLGAP2) 
have been associated with ASD64,189-192. In line with SHANK mice models, Dlgap2-/- mice show 
reduced spine density and a downregulation of synaptic proteins such as HOMER1193.  
 
Another postsynaptic density scaffolding protein, linking regulation of the synaptic actin 
cytoskeleton to ASD, is DISC1 (disrupted in schizophrenia 1) (DISC1). DISC1 plays a major 
role in early brain development by regulating a number of essential neurodevelopmental events 
including cell proliferation, neurite outgrowth, synapse formation and neuronal migration194,195. 
DISC1 maintains spine morphology and function by regulating Rac-1 activator, Kalirin-7 (Kal-
7), access to Rac1196 (Figure 5). Kal-7/Rac1 cascade and Rac-1 activation in response to NMDA 
receptor activation in both neuronal cultures and rat brain in vivo196 are important for the activity–
dependent spine morphology and functional plasticity197. In addition to schizophrenia, genetic 
association and rare variants in DISC1 have been associated with autism and Asperger’s 
syndrome198.  
 
IRSp53 (also known as brain-specific angiogenesis inhibitor 1-associated protein 2, BAIAP2) 
is a multi-domain scaffolding and adaptor protein that has been implicated in the regulation of 
membrane and actin dynamics in dendritic spines, filopodia and lamellipodia. Accumulating 
evidence indicates that IRSp53 is an abundant component of multi-protein complexes on the 
postsynaptic side of excitatory synapses199 and directly binds to PSD-95 and Shank/ProSAP200-202 
(Figure 5). IRSp53 has been suggested to form a platform-like structure that organizes synaptic 
signaling to regulate dendritic spines through its ability to interact with F-actin and actin 
regulatory proteins155,200,203,204. 
Both genetic association between the BAIAP2 gene and autism205 and a rare deletion in the 
BAIAP2 has been identified in association with autism206. IRSp53 has been implicated also in 
other psychiatric disorders, including ADHD (attention deficit/hyperactivity disorder)207,208 and 
schizophrenia209,210. Overexpression of IRSp53 in cultured neurons increases the density of 
dendritic spines without affecting spine length or width. Conversely, short-interfering RNA-
mediated knockdown of IRSp53 reduces spine density, length, and width200. In agreement with 
this, and indications from other in vitro studies199-201,211, IRSp53−/− mice have fewer dendritic 
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spines and perforated PSDs (a measure of maturity) in the hippocampus212. Hippocampal neurons 
from IRSp53−/− mice have been reported to exhibit stabilized F-actin and suppressed basal cofilin 
activity (i.e. increased phosphorylation as a measure of inactivity)212. These animals also display 
enhanced NMDA receptor function, as well as social and cognitive deficits similar to those 
observed in psychiatric disorders212. Pharmacological suppression of NMDA receptor function 
can improve these behavioral deficits212, prompting the hypothesis that defective actin/membrane 
modulation in IRSp53-deficient dendritic spines could lead to social and cognitive deficits 
through NMDA receptor dysfunction. 
 
Although this review focuses on ASD-associated mutations that affect the actin cytoskeleton in 
dendritic spines, it is important to note that there are some indications that postsynaptic proteins 
may indirectly affect the presynaptic actin cytoskeleton and presynaptic function. The 
presynaptic terminal is a subcellular axonal compartment dedicated to releasing neurotransmitters 
upon neuronal activation through synaptic vesicle (SV) exocytosis. The fusion of SVs with the 
active zone membrane is followed by SV recycling through endocytosis213,214. Actin is abundant 
in the presynapses and performs active roles in vesicle trafficking and the development of 
presynaptic terminals203,215. Actin interaction with synapsin, which is phosphorylated upon 
neuronal activity is crucial for the organization of the SV pools within the presynaptic nerve 
terminal216. In particular, despite being a postsynaptic protein, SHANK3 may indirectly affect the 
presynaptic actin-synapsin signaling pathway through trans-synaptic activity involving neurexin-
neuroligin (NRXN-NL) protein complexes217: ASD-associated mutations in Shank3 disrupt 
postsynaptic AMPA and NMDA receptor signaling and also interfere with the ability of Shank3 
to signal across the synapse to alter presynaptic structure and function via the NRXN-NL2 trans-
synaptic pathway. Additionally, NL3 is a postsynaptic protein that interacts with NRXN in the 
presynaptic neuron that also regulates synaptic morphogenesis. Mutations in the genes encoding 
NRXNs and NLs have further been linked to ASD218. These reports indicate that ASD-associated 
mutations in a subset of synaptic proteins may target core cellular pathways that coordinate the 
pre- and postsynaptic matching and maturation of excitatory synapses in the CNS. Interestingly, 
variants and mutations in other genes coding presynaptic proteins connected to actin, such as 
PRICKLE1 and syntaxin binding protein 5 (STXBP5, also known as tomosyn), have also been 
associated with ASD43,192,219-222. For example, Prickle1+/- mice exhibit autism-like behavior, 
which might result from disrupted interaction with synapsin and dysregulation of SVs221.  
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Table I. Summary of autism-associated actin-regulatory human genes. 
Gene 
Symbol 
 
Protein name/ 
Aliases 
Role Chr. 
band 
Genetic Category*, 
Gene Score (GS)# 
References 
Actin polymerization and depolymerization 
CTTNBP2 Cortactin binding 
protein 2 
Regulates formation and 
maintenance of dendritic spines via 
cortactin function on F-actin 
branching and stabilization. 
7q31.
31 
Rare single gene variant, 
GS3 
36,37,41,43,223 
CYFIP1 Cytoplasmic 
FMR1 
interacting 
protein 1 
Regulates actin cytoskeleton 
remodeling connected with 
dendritic spine formation. 
15q11
.2 
Multigenic CNV, 
rare single gene variant, 
genetic association 
 
47,71,224 
 
DIAPH3 Diaphanous-
related formin 3, 
DRF3, mDia2 
Regulates actin dynamics during 
dendritic spine elongation together 
with other actin regulatory proteins. 
13q21
.2 
Rare single gene variant, 
GS5 
80,82,83,225 
GSN Gelsolin Severs F-actin filaments and 
regulates neurogenesis and neuronal 
migration. 
9q33.
2 
Rare single gene variant 84,85,91 
Actin cross-linking 
ACTN4 
 
-actinin-4 F-actin cross-linking to remodel 
dendritic protrusions and regulate 
dendritic morphogenesis. 
19q13.2 Rare single gene variant 10,105,118 
CAMK2A 
 
Calcium/calmod
ulin dependent 
protein kinase II 
alpha 
 
May stabilize and maintain the 
dendritic spine structure together 
with CaMKIIβ through actin 
bundling and by inhibiting the 
binding of other actin regulators. 
5q32 Rare single gene variant, 
GS4 
118,120,121 
VIL1 
 
Villin 1 
 
Caps, severs, and bundles actin 
filaments. Function in neurons 
unknown. 
2q35 Rare single gene variant, 
GS3 
43 
Actin-binding myosin motors 
MYO16 
 
Myosin XVI 
 
Neuronal migration during 
development and neurite 
outgrowth 
13q33.3 Genetic association, 
rare single gene variant, 
GS4 
129-132 
MYO9B Myosin IXB, 
myr5 
 
Role in dendritic spine 
morphogenesis is unknown, but 
may augment spine formation and 
maturation. 
19p13.1
1 
Rare single gene variant, 
GS3 
 
43,118,137 
MYH4 Myosin heavy 
chain IIb isoform  
Predominant role in skeletal 
muscles.  Function in neurons 
unknown. 
17p13.1 Rare single gene variant, 
GS4 
 
 
143,226 
 
Cohesive proteins, linking F-actin to other support proteins 
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DMD Dystrophin 
 
Bridges F-actin and the extra-
cellular matrix and may form a 
component of inhibitory 
synapses. 
Xp21.2-
p21.1 
Syndromic, 
Genetic 
association, 
Rare single gene variant 
 
146 
 
UTRN Utrophin Structural support for dendritic 
spine membranes. 
6q24.2 Rare single gene variant 10 
Synaptic scaffolding proteins linked to the actin cytoskeleton  
SHANK1 SH3 and 
multiple ankyrin 
repeat domains 1 
Structural and functional 
organization of the dendritic spine 
and synaptic junction 
19q13.3
3 
Rare single gene variant, 
GS3 
 
223,227 
SHANK2 SH3 and 
multiple ankyrin 
repeat domains 2 
Controls dendritic spine volume 
and branching and synaptic 
transmission. 
11q13.3
-q13.4 
 
Rare single gene variant, 
GS2 
64,228 
SHANK3 SH3 and 
multiple ankyrin 
repeat domains 3 
Controls dendritic spine 
formation and maturation. 
 
22q13.3
3 
 
Rare single gene variant, 
genetic association, 
syndromic, Multigenic 
CNV 
91,168,173,174,229 
DISC1 Disrupted in 
Schizophrenia 1, 
DISC1 
Controls early brain development 
by regulating neurite outgrowth, 
synapse formation and neuronal 
migration 
1q42.2 Rare Single Gene 
Mutation, Syndromic, 
Genetic Association 
194,195,198 
 
BAIAP2 
 
BAI1-associated 
protein 2, 
IRSp53 
Regulates membrane and actin 
dynamics in dendritic spines. 
17q25.3 Rare single gene variant, 
genetic association, GS5 
205,206 
Trans-synaptic pathway and links to presynaptic actin cytoskeleton  
NRXN1 Neurexin 1 Cell adhesion and receptors. 
 
2p16.3 Rare single gene variant, 
genetic association, 
syndromic 
 
230-233 
 
NRXN2 Neurexin 2 
 
Cell adhesion and receptors. 
 
11q13.1 
 
Rare single gene variant, 
GS4 
234 
NRXN3 Neurexin 3 Cell adhesion and receptors. 
 
14q24.3
-q31.1 
 
Rare single gene variant, 
genetic association, GS3 
235 
NLGN1-3 Neuroligin 1-3 Regulates spines and synaptic 
plasticity. 
3q26.31, 
17p13.1, 
Xq13.1 
Rare single gene variant, 
genetic association, 
GS2/4 
217,236-238 
PRICKLE1 Prickle homolog 
1 (Drosophila) 
Involved in axonal and dendritic 
formation 
12q12 
 
Syndromic, rare single 
gene variant, GS3 
192,221,222 
STXBP5 Syntaxin binding 
protein 5 
Associates with F-actin and is 
involved in synaptic vesicles 
exocytosis 
6q24.3 
 
Rare single gene variant, 
GS3 
 
43,192,220 
 
*Rare single gene variants indicate disruptions/mutations, and submicroscopic deletions/duplications directly linked 
to ASD. Syndromic indicates genes implicated in syndromes in which a significant subpopulation develops 
symptoms of autism (for example in Fragile X Syndrome). Association indicates small risk-conferring common 
polymorphisms identified from genetic association studies in idiopathic ASD.  
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#
GS= SFARI Gene Score gives an estimation of the strength of the evidence indicating that a gene is relevant for 
ASD. GS1, High confidence; GS2, strong candidate; GS3, suggestive evidence; GS4, minimal evidence; GS5, 
hypothesized but untested; GS6, evidence does not support a role. The table is modified from the SFARI gene 
collection (https://sfari.org/).  
 
 
2.6 RhoGTPase regulation  
 
The Rho family of GTPases is a family of small signaling G-proteins that are central regulators of 
intracellular actin dynamics. The most extensively studied members of the family are Cdc42, 
RhoA and Rac1, which in fibroblasts control filopodia and microspike formation, mediate focal 
adhesion and stress fiber formation, and induce membrane ruffling and the formation of 
lamellipodia, respectively239. Through their role in controlling F-actin dynamics, small 
RhoGTPases and their regulators, GTPase-activating proteins (GAPs) and guanine-exchange 
factors (GEFs), are critical mediators of dendritic arborization, spine morphogenesis, growth 
cone development, axon guidance240-245 and neuronal survival246. Mutations in Rho family 
GTPase regulators in particular are frequently associated with neurological diseases241,247-249.  
 
SLIT-ROBO Rho GTPase-activating protein 3 (SrGAP3) (SRGAP3) is ubiquitously 
expressed in the developing nervous system250,251. The full-length human SrGAP3 protein 
contains an iF- Bin1/amphiphysin/Rvs167 (BAR) domain (involved in membrane binding), a 
Rac1 GAP domain and an SH3 domain interacting with Robo1/2, WAVE1 and lamellipodin. 
SrGAP3 binds WAVE1 and downregulates Rac1 signaling252-254 (Figure 6). Knocking out 
SrGAP3 decreases the number of dendritic filopodia in early development, and it is therefore 
plausible that SRGAP3 deficiency also leads to decreased dendritic spine density in human 
patients255. Two de novo missense variants in the SRGAP3 gene (one predicted to be probably 
damaging, and the other predicted to be possibly damaging) were identified in ASD probands 
from the Simons Simplex Collection118. In addition, the authors reported a de novo point 
mutation E469K (glutamic acid to lysine), which changed negatively charged glutamate to 
positively charge lysine at the end of the iF-BAR domain.  
 
Oligophrenin1 (OPHN1), also referred as RhoGTPase activating protein 41 ARHGAP41, has 
been identified on the X chromosome region q12256. Ophn1 is expressed during early 
development, from embryonic day 10 (E10) in the mouse257. In situ hybridizations on mouse 
embryos have revealed a strong signal in the neural tube and the developing brain. In the adult, 
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Ophn1 is widely expressed throughout the brain but is concentrated in the olfactory bulb, the 
hippocampus and the cerebellum. In young cultured neurons, oligophrenin1 colocalizes with the 
actin cytoskeleton in the growing tip of dendrites257, and is detected in the axon, dendrites and 
dendritic spines of mature neurons258. In vitro, the use of RNA interference methods has revealed 
the important role of oligophrenin1 in the regulation of dendrite morphogenesis and the 
regulation of dendritic spine maturation258. Notably, the downregulation of oligophrenin1 
expression in rat hippocampal slices leads to a decrease in spine length without affecting spine 
density258. Although oligophrenin1 has the capacity to interact with the three RhoGTPases, its 
action on spine morphogenesis depends on its negative regulation of RhoA, leading to the 
activation of Rho-associated coiled-coil containing protein kinase (ROCK) and spine growth258. 
The role of oligophrenin1 has been confirmed in vivo; knockout Ophn1-/y mice present a 
decreased complexity of the dendritic tree together with a reduction in the density of mature 
dendritic spines259. These animals also exhibit a decreased adult neurogenesis. Treatment of 
Ophn1-/y cultured brain slices with an inhibitor of ROCK/PKA, Fasudil, restores dendritic spine 
morphology and adult neurogenesis260. At the postsynapse, oligophrenin1 colocalizes and 
interacts with the scaffolding protein HOMER1b/c256,261 (Figure 6). The disruption of this 
interaction by the expression of mutated forms of one or the other partner causes the 
mispositioning of the endocytic zone in the PSD and an impaired recycling of AMPA 
receptors261. Oligophrenin1 also plays a role in the correct functioning of the presynapse. In the 
axon terminus, it interacts with endophilin A1 and triggers SV retrieval262. In vivo, mice in which 
Ophn1 is disrupted exhibit deficits in presynaptic plasticity due to dysregulation of the 
cAMP/PKA signaling pathway263. Oligophrenin1 belongs to the GTPase regulator associated 
with focal adhesion kinase (GRAF) protein subfamily, characterized by a N-terminal BAR 
domain, a pleckstrin homology (PH) domain and a GAP domain, which negatively regulates 
RhoA264. Several case studies have provided evidence of potential loss of function mutations – 
either deletion or insertions – in the region coding for the BAR domain linked to intellectual 
disability, suggesting an important role of this domain in oligophrenin1 function256,264,265. The 
BAR domain could indeed play several roles, notably in the control of the membrane curvature 
for SV recycling or the binding and regulation of RhoA in conjunction with the PH domain. 
Finally, rare missense variants in OPHN1 gene have been identified in patients with ASD206,266. 
 
Although this review focuses on the link between actin in dendritic spines, and thus excitatory 
synapses, and ASD, several genes that regulate the formation of inhibitory synapses are also 
related to ASD. One example is Cdc42 guanine nucleotide exchange factor (GEF) 9 
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(ARHGEF9), also known as collybistin or posterior end mark 2 (PEM2). ARHGEF9 was first 
identified in a yeast two hybrid screen as an interactor with the scaffolding protein gephyrin267,268 
(Figure 6). ARHGEF9 contains a diffuse B-cell lymphoma (Dbl) homology (DH) domain that 
interacts with RhoGTPases, a PH domain and a SH3 domain269. ARHGEF9 is a gephyrin binding 
partner predominantly expressed in the brain. Its expression is induced during the second half of 
murine embryogenesis, in postmitotic neurons of the cortex269,270. Multiple isoforms have been 
identified, based on different sizes and the presence or absence of the SH3 domain269,271. The PH 
domain of ARHGEF9 binds to phosphatidylinositol 3-monophosphate and 4-monophosphate 
(PI3P, PI4P)269, whereas the SH3 domain inhibits this membrane-targeting function271. However, 
PH affinity to PI binding is not sufficient for the correct targeting of the protein to the plasma 
membrane, and the binding of ARHGEF9 to gephyrin is therefore necessary for its membrane 
targeting. Xiang, et al. 269 (2006) proposed a model in which the activation of PI3K by an 
unknown presynaptic factor results in an increased phosphatidylinositol 3,4,5-triphosphate 
concentration at the plasma membrane. This leads to the recruitment of ARHGEF9, which then 
initiates actin cytoskeleton regulation and gephyrin recruitment that in turn triggers the clustering 
of glycine receptors. A mutation in the PH domain linked to intellectual disability has been 
shown to alter the binding of ARHGEF9 to PI3K, causing the loss of gephyrin clustering 
affinity272. A mouse model genetically ablated for Arhgef9 displays a loss a postsynaptic 
gephyrin and GABA receptors, together with a disruption of synaptic plasticity and changes in 
anxiety and learning behavior273. The ASD-associated postsynaptic adhesion protein NL2 is 
specific for inhibitory synapses274. It binds to gephyrin and functions as a specific activator of 
ARHGEF9 by relieving the SH3-mediated inhibition of its membrane targeting function. The 
recruitment of gephyrin and ARHGEF9 to the synaptic membrane by activated NL2 therefore 
triggers the clustering of GABA and glycinergic receptors271. ARHGEF9 also binds to mTOR, a 
regulator of essential cellular processes such as cell growth and protein synthesis. The interaction 
of ARHGEF9 with mTOR promotes the activation of the mTOR complex 1 (mTORC1) signaling 
pathway and protein synthesis. Deregulation of the mTORC signaling pathway results in severe 
neuronal disorders, deficits observed in a patient presenting an ARHGEF9 complete deletion 
associated with marked intellectual disability275. Furthermore, several case studies present 
patients with various modification of chromosomal region Xq11, the site of the gene that codes 
for ARHGEF9, associated with severe neurological traits and ASD276-278. 
 
ARHGAP15 (ARHGAP15) is a Rac1 regulator that is expressed in the pyramidal cells and the 
GABAergic interneurons of the hippocampus in adult mice279. ARHGAP15 acts as a GAP for 
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Rac1 with which it interacts through its C-terminus domain279,280. It has also been shown to 
interact with the Rac1 downstream effectors PAK1/2 via its N-terminus (Figure 6). This 
interaction leads to a mutual inhibition of the two proteins, resulting in decreased GTPase 
activity280. The genetic ablation of Arhgap15 in the mouse hippocampus leads to decreased 
complexity of the dendritic tree of neurons. Moreover, cultured hippocampal neurons from rat 
embryos knocked down for Arhgap15 have fewer spines, although the morphology of these 
spines is not changed compared to control neurons279. ARHGAP15 was linked to ASD in a case 
study of a young man with marked intellectual disability. Here, a severe 6 Mb de novo deletion 
was discovered in the 2q22 locus, covering several genes including ARHGAP15281. 
 
ARHGAP32 (ARHGAP32), also known as RICS or p250GAP, is expressed in the cerebral 
cortex during early postnatal development282. Knockdown of Arhgap32 in cultured cortical 
neurons by miRNA has demonstrated its role in the regulation of the dendritic tree complexity282. 
Arhgap32 gene silencing in cultured hippocampal neurons has been shown to produce an 
increased dendritic spine head width without affecting the length of the spines or their density 
along the dendritic shaft283. In contrast, a gain-of-function experiment in hippocampal neurons 
overexpressing ARHGAP32 led to a decrease in the spine width but an increase in the neck 
length283. ARHGAP32 interacts with the NR2B subunit of the NMDA receptor and promotes the 
activation of the RhoGTPase RhoA in response to NMDA activation283 (Figure 6). Several 
genetic studies have identified de novo LGD mutations in the ARHGAP32 gene in ASD patients, 
with notably patients presenting a 11q deletion characteristic of Jacobsen syndrome284,285. 
 
ARHGAP33 (ARHGAP33) (also known as TC10β/CDC42 (TC)-GAP, NOMAGAP or SOX26) 
is concentrated in the dendritic spines of cortical pyramidal neurons where it colocalizes with 
PSD-95286 (Figure 6). Although ARHGAP33 has not been genetically linked to ASD, its genetic 
ablation in mice results in major deficits in social behavior, a typical autistic trait286. Moreover, 
ARHGAP33 regulates several neuronal morphogenesis mechanisms that are closely related to 
ASD cellular phenotypes. Most notably, ARHGAP33 regulates dendrite morphogenesis, with 
Golgi impregnations of knockout mouse brains providing evidence of its involvement in the 
promotion of dendritic complexification287,288. This is achieved by the inactivation of Cdc42 by 
ARHGAP33, which triggers a molecular signaling cascade that leads to the activation of the actin 
depolymerization factor cofilin, and the regulation of the branching of the dendritic tree289. More 
recently, two studies have reported the important role of ARHGAP33 in regulating spine 
morphogenesis. First, Arhgap33-/- mice exhibit an impaired spine development, with a reduced 
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number of total spines together with a decreased proportion of mature spines. In these mice, the 
trafficking and surface expression of the BDNF receptor TrkB are impaired, resulting in a deficit 
in spine and synapse formation287. The second study shows that Arhgap33-/-mice also present 
morphological variations of their dendritic spines, with a longer length of the spine neck without 
modification of the head width and a decrease in the density of synapses containing PSD-95286. 
The deletion of Cdc42 does not restore this phenotype. Co-immunoprecipitations performed on 
cortical lysates of wildtype mice have revealed the interaction of ARHGAP33 with the 
scaffolding protein PSD-95. ARHGAP33 regulates the phosphorylation and localization of PSD-
95, in association with a loss of AMPA receptors at the synaptic membrane286. The recruitment of 
AMPA receptors at the synapse leads to the strengthening and the maturation of spines via the 
regulation of signaling pathways that modulate the actin cytoskeleton290. 
 
ARHGAP24 (ARHGAP24), also known as  Rac1 regulator, was identified in 2004 based on its 
homology to ARHGAP22291. ARHGAP24 is a binding partner of filamin A, an F-actin cross-
linking protein292. ARHGAP24 is a canonical target of the nonsense-mediated mRNA decay 
(NMD) factor UPF3B that regulates the degradation of mutated transcripts, and mutations in the 
genes coding for UPF3B have been linked to intellectual disability293. ARHGAP24 regulates 
neuronal morphology. Notably, overexpression of ARHGAP24 in murine hippocampal neurons 
leading to decreased axon outgrowth, together with a reduction in the number of dendritic 
termini293. This suggests that ARHGAP24 could play a role in the development of dendritic 
spines but this has not yet been demonstrated. A de novo deletion in the locus 4q21.23q21.3, a 
region that only harbors the gene which codes for ARHGAP24, has been identified in ASD 
patients294. 
 
Other RhoGTPase regulating proteins have been linked to ASD. For example, two CNVs have 
been isolated in the gene ARHGAP11B coding for ARHGAP11B, in ASD patients71. 
ARHGAP11B has been implicated in the evolutionary expansion of the neocortex. Its genetic 
link to ASD and its presence in the brain during development suggest a potential role for 
ARHGAP11B in dendritic spine morphogenesis and plasticity, but this is still to be 
demonstrated295,296.  
 
Finally, other actors of the small GTPases superfamily and their regulators are involved in the 
development of dendritic spines. Among them, the Synaptic GTPase activating protein 1 
(SynGAP1) (SYNGAP1), an excitatory synapse-specific RasGAP, is enriched at excitatory 
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synapses where it associates with PSD-95 and regulates cofilin activity297-299 (Figure 6). A 
disruption in the balance between excitatory and inhibitory neurotransmission in the developing 
brain has been linked with autism, mental retardation and intellectual disability. Excitatory 
synapse strength is regulated by controlling the number of postsynaptic AMPA receptors in the 
CNS. SynGAP1 regulates AMPA receptor trafficking, the number of silent synapses, and 
excitatory synaptic transmission in cultured hippocampal and cortical neurons. In response to 
CaMKII phosphorylation, SynGAP1 maintains dendritic spine stability through its role in 
regulating Ras/Rap activity and mitogen-activated protein kinases (MAPK) signaling299-302. 
Overexpression of SynGAP1 in neurons decreases synaptic AMPA receptor surface expression 
and insertion into the plasma membrane, and decreases AMPA receptor-mediated miniature 
excitatory postsynaptic currents (mEPSCs)301,303,304. Cultured hippocampal neurons from 
syngap1+/− and syngap1−/− mice, as well as from neuronal cultures treated with SynGAP1 
siRNA, exhibit increased actin polymerization and phospho-cofilin levels, and an increase in the 
synaptic strength and the in number of “mushroom” spines297,301,305, which is one of the notable 
classes of spine shape in addition to "thin", "stubby", and "branched". SYNGAP1 
haploinsufficiency has been found in individuals with autism, intellectual disability, and a 
specific form of epilepsy306. In mice, SynGAP1 accelerates the maturation of dendritic spines 
leading to disruptions in synaptic transmission and cognitive function307-310. Several de novo 
mutations of SYNGAP1 have also been associated with ASD43,64,306,311-315. Together these results 
indicate that disruption of SynGAP1 activity in regulating F-actin structure within spines leads to 
spine destabilization and changes in spine morphology. 
 
Table II. Summary of autism-associated small GTPases superfamily members regulating actin 
cytoskeleton. 
Gene 
Symbol 
 
Protein name/ 
Aliases 
Role Chr. 
band 
Genetic Category*, 
Gene Score (GS)# 
References 
SRGAP3 SLIT-ROBO 
Rho GTPase 
activating protein 
3 
GAP for Rac1 and possibly for 
Cdc42, but not for RhoA. May 
attenuate Rac1 signaling in neurons. 
Plays a role in spine initiation. 
3p25.
3 
 
Rare Single Gene 
Mutation 
GS4 
118 
OPHN1 Oligophrenin 1 A RhoA-GAP involved in cell 
migration and outgrowth of axons 
and dendrites. 
Xq12 Rare Single Gene 
Mutation 
GS3 
206,266 
ARHGEF9 Cdc42 guanine 
nucleotide 
exchange factor 
9, collybistin  
Cdc42-GEF, which promotes the 
formation of GPHN clusters.  
 
Xq11.
1-
q11.2 
Rare Single Gene 
Mutation 
 
316,317 
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ARHGAP1
1B 
Rho GTPase 
activating protein 
11B  
Activates Rho-like small 
GTPases. Function in neurons 
unknown. 
15q13.2 Rare Single Gene 
Mutation 
 
71 
ARHGAP1
5 
Rho GTPase 
activating protein 
15 
Rac1-GAP regulates positively 
complexity of the dendritic tree and 
spine density. 
2q22.
2-
q22.3 
Rare Single Gene 
Mutation 
GS6 
143,318 
ARHGAP2
4 
Rho GTPase 
activating protein 
24, FilGAP 
Rac1-GAP, possibly having a role 
in axon outgrowth and dendritic 
spine formation.   
4q21.23
-q21.3 
Rare Single Gene 
Mutation 
GS5 
319 
ARHGAP3
2 
Rho GTPase 
activating protein 
32, RICS, 
p250GAP 
A neuron-associated RhoA-GAP 
that regulates dendritic spine 
morphology. 
11q24.3 
 
Rare Single Gene 
Mutation, Functional 
GS4 
43,223 
ARHGAP3
3 
Rho GTPase 
activating protein 
33, TC10-beta-
GAP, 
NOMAGAP, 
SOX26 
Cdc42-GAP involved in the 
regulation of the branching of the 
dendritic tree as well as in 
dendritic spine and synapse 
formation. Involved in 
intracellular trafficking. 
19q13.1
2 
 
Rare Single Gene 
Mutation, Functional 
GS5 
320 
SYNGAP1 
 
Synaptic Ras 
GTPase 
activating protein 
1 
An excitatory synapse-specific 
Ras-GAP regulates AMPA 
receptor trafficking and synaptic 
transmission.  
6p21.32 
 
Rare Single Gene 
Mutation, Syndromic 
GS1 
43,64,223,226,312-
314,321 
*Rare single gene variants indicate disruptions/mutations, and submicroscopic deletions/duplications directly linked 
to ASD. Syndromic indicates genes implicated in syndromes in which a significant subpopulation develops 
symptoms of autism (for example in FXS).  
#
GS= SFARI Gene Score gives an estimation of the strength of the evidence indicating that a gene is relevant for 
ASD. GS1, High confidence; GS2, strong candidate; GS3, suggestive evidence; GS4, minimal evidence; GS5, 
hypothesized but untested; GS6, evidence does not support a role. The table is modified from the SFARI gene 
collection (https://sfari.org/).  
 
3. Treatment  
 
The studies reviewed here suggest that dysregulation of actin cytoskeleton-related pathways that 
control dendritic structure may contribute significantly to the pathogenesis of ASD. Although 
ASDs show a high rate of heritability, genetic research alone has not been able to provide a 
complete understanding of the underlying pathophysiology in the pursuit of unique 
pharmacogenetic approaches. ASDs are genetically and clinically heterogeneous and effective 
medications to treat the core symptoms are still lacking. However, a number of drugs and 
alternative strategies have shown some promise.  
Genetic and pharmacological interventions in mouse models of ASD, including TSC322, FXS323, 
Rett syndrome324,325 and Angelman syndrome326, as well as in Shank2−/− mice carrying a mutation 
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identical to the ASD-associated microdeletion in the human SHANK2 gene327, have shown 
promise in improving ASD phenotypes, offering hope for the development of therapeutics for 
ASD. Autism-like social deficits and repetitive behaviors have been rescued by targeting actin 
regulators in Shank3-deficient mice178. This autism-mouse model shows significantly diminished 
NMDA receptor function and synaptic distribution in the prefrontal cortex, as well as a marked 
loss of cortical actin filaments associated with reduced Rac1/PAK activity and increased cofilin 
activity. The social deficits and NMDA receptor hypofunction displayed by the mice was rescued    
by inhibiting cofilin activity or by activating Rac1178. In agreement with these results, treatment 
of Shank2−/− mice with 3-cyano-N-1,3-diphenyl-1H-pyrazol-5-yl benzamide (CDPPB), which 
increases the responsiveness of mGluR5 to glutamate and enhances NMDA receptor function328, 
markedly improves autistic-like social behavior327. Targeting the deficits of actin cytoskeleton in 
the most common inherited form of autism and intellectual disability, FXS, has also shown 
promise329. Fragile X syndrome is the most common type of inherited mental retardation caused 
by the absence of FMRP protein, a RNA-binding protein implicated in the regulation of mRNA 
translation and transport, leading to protein synthesis. The Fmr1 knockout mice display 
hyperactivity, seizures, repetitive behaviour, and abnormal spine densities similarly to the human 
condition. Among many other proteins, FMRP negatively regulates expression of Rac1 and 
pharmacological manipulation of Rac1 partially reverses the altered long-term plasticity seen in 
Fmr1 KO mice20. Accordingly, by inhibiting the Rac1 effector, group I p21-activated kinase 
(PAK) protein, which regulates spines through modulation of actin cytoskeleton dynamics, with a 
drug called FRAX486, the dendritic spine phenotype is reversed in Fmr1 KO mice329. PAK 
inhibition also rescues seizures and behavioural abnormalities such as hyperactivity and repetitive 
movements, indicating that targeting spine abnormalities can also treat neurological and 
behavioural symptoms329. Remarkably, Dolan and colleagues329 showed in 2013 that a single 
administration of FRAX486 is sufficient for the phenotype rescue in adult Fmr1 knockout mice, 
demonstrating that a postdiagnostic therapy could be possible for FXS adults. 
Nutritional factors affecting ASD have also recently received attention. An increase in 
postsynaptic zinc (Zn) level induced by clioquinol (a Zn chelator and ionophore), and the 
subsequent activation of NMDA receptors through the tyrosine kinase Src, rescued social 
interaction in Shank2−/− mice330. Shank3 mutations and large duplications both cause a spectrum 
of neuropsychiatric disorders, indicating that the correct protein expression level is critical for 
normal brain function. Shank3 transgenic mice, modeling a human SHANK3 duplication, exhibit 
manic-like behavior and seizures consistent with a synaptic excitatory/inhibitory imbalance, 
similar to the symptoms of two hyperkinetic disorder patients carrying the smallest SHANK3-
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spanning duplications reported so far179. SHANK3 was found to directly interact with Arp2/3 and 
to increase F-actin levels in the Shank3 transgenic mice, and treating the mice with the mood-
stabilizing drug valproate, but not lithium, ameliorated the manic-like behavior179. Consistent 
with previous results showing that NMDA receptor membrane delivery and stability depend on 
the integrity of actin cytoskeleton331, these findings further highlight that the dysregulation of 
synaptic actin filaments and the loss of synaptic NMDA receptors contribute to the manifestation 
of autism-like phenotypes, and thus provide strategies for the treatment of autism178. 
Drug trials in human patients have also taken place. One example is the recent therapeutic study 
on TSC patients with autistic symptoms332. TSC disease is caused by loss-of-function mutations 
in TSC1 or TSC2 genes94,95, which code the proteins TSC1 and TSC2. TSC1 and TSC2 bind 
together to form a complex that inhibits mTOR, which controls translation, proliferation, and cell 
growth333. Treating children and adolescent TSC patients displaying emotional and behavioral 
symptoms and refractory epilepsy with everolimus, an inhibitor of mTOR, produced beneficial 
effects in relation to the autistic, ADHD, and depressive symptoms, as well as controlling the 
seizures332. 
Consistent with the hypothesis that excessive metabotropic glutamatergic signaling in autism may 
cause some of the core symptoms of the disorder, several studies using mGluR5 antagonists in 
animal models of autism have reported beneficial behavioral improvements, with varying side 
effects in mice334-336. The mGluR5 antagonists that have been evaluated for efficacy in FXS are 
an example of therapeutics that have been developed to treat a specific disorder, but that might 
have more general applicability. However, challenges to translate results from FXS animal 
models to humans include uncertainties regarding optimal patient selection, age of treatment 
onset, dosages and durations of treatment, differences in pharmacokinetics and 
pharmacodynamics, dose-limiting side effects, and biomarkers of CNS improvement. In recent 
years, there have been some preliminary results to indicate that targeted treatment with mGluR5 
antagonists may be beneficial for autistic children337. However, to date, there are no reports of 
successful randomized, double-blind, placebo-controlled mGluR5 antagonist drug trials on 
humans. Defining how different ASD-associated mutations disrupt synaptic structure and 
function may be crucial for the development of therapeutics that target a particular molecular 
defect. Understanding the molecular basis of ASD will hopefully allow rational development of 
therapies for a spectrum of autistic disorders.  
 
4. Final words 
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Here, we reviewed the literature regarding a number of ASD-associated genes, which encode 
proteins that regulate actin dynamics. Although synaptic deficiency is only one possible cause 
underlying the symptoms of ASD, in this review we focused on the roles of ASD-associated actin 
regulators in the development and function of excitatory synapses, as it is becoming clear from 
human genetic and brain tissue studies, as well as from mouse models, that dysfunction of the 
actin cytoskeleton at excitatory spine synapses is likely to be a molecular pathology that is shared 
across different neurodevelopmental and psychiatric disorders. As the autistic symptoms can be 
rescued by either manipulating actin regulators or by reversing the dendritic spine density or 
morphology further emphasizes the importance to understand the role of synaptic actin regulation 
in ASD. 
Based on this review, we draw three main conclusions. First, many actin regulators associated 
with ASDs have a role in the regulation of synaptic structure and/or function, suggesting that a 
perturbation in the interplay between the PSD and dendritic spine actin cytoskeleton is one of the 
key cellular processes in ASD pathology. Actin regulators such as SHANKs, can also act as 
synaptic scaffolding platforms, or they can link postsynaptic scaffolding proteins, such as PSD-
95 to the actin cytoskeleton, as in the case of IRSp53/BAIAP2. Alternatively, proteins can 
mediate the effects of various receptors on the cytoskeleton; DISC1 mediates the effects of 
NMDA receptors on Rac1 signaling, whereas -actinin-4 facilitates mGluR-induced actin 
remodeling105. Furthermore, some proteins, such as gelsolin and -actinin-4, can be regulated by 
a neuronal activity-induced increase in postsynaptic Ca2+ concentration. Defective stabilization of 
neuronal structures may also be important in ASD pathology338 as many associated proteins link 
actin cytoskeleton either to plasma membrane (Irsp53, -actinin-4) or to the extracellular matrix 
(dystrophin and utrophin) or regulate the connection between actin filaments and extracellular 
matrix (SHANKs)170. 
Our second conclusion is that Rho signaling plays a central role in ASD pathology. Here, we 
evaluated nine different Rho regulators, most of which have well-established roles in dendritic 
spine or synapse development. These GEFs and GAPs are often linked to synaptic proteins and 
mediate the changes in actin dynamics that occur in response to synaptic activity. Finally, we 
report that the information about the function of different proteins in the brain and in particular 
the effects of mutations on synapses is still very limited and, therefore, it is difficult to conclude 
any common defects which would be consistent between different causative genes. However, it is 
clear that, based on the different pathways associated with ASD, the causative gene products 
participate in synaptic plasticity by modulating synaptic strength and/or number, and that, in ASD 
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animal models, mutations in the ASD-associated genes result in synaptic activity and synaptic 
density that are either too high or too low. 
To better understand the pathophysiology of ASDs, we would need comprehensive information 
on a) the functions of ASD-associated proteins in the brain, b) how mutations affect the 
expression level and function of these proteins, c) how mutations affect their function in neurons, 
and d) how changed neuronal function impacts the circuits and behavior. We currently have a 
good overview of the different pathways affected in ASD and the next step will be to characterize 
the proteins encoded by these genes, as well as the effects of mutations. The recent CAMK2A 
study121 provides a good example on how we should proceed with each protein and mutation. 
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Figure legends 
Figure 1. Regulators of actin polymerization and depolymerization. CYFIP1 and DRF3 
regulate actin polymerization while GSN severs F-actin filament. CTTNB2 is involved in the 
branching and the stabilization of the actin microfilaments. In colour are the proteins linked to 
ASD and in grey their cytoplasmic partners. 
Figure 2. Actin cross-linking proteins. ACTN4 antiparallel dimers are a link between 
membrane receptors and actin cytoskeleton. Villin is a Ca2+-regulated actin binding protein. In 
colour are the proteins linked to ASD and in grey their cytoplasmic partners. 
Figure 3. Actin-binding myosin motors. MYO16 is a molecular motor with an ATPase activity; 
MYO9B is a motorized RhoGAP that inhibits RhoA. In colour are the proteins linked to ASD 
and in grey their cytoplasmic partners. 
Figure 4. Dystrophin and Utrophin. These cohesive proteins form a link between the 
extracellular matrix and the cytoplasm. In colour are the proteins linked to ASD and in grey their 
cytoplasmic partners. 
Figure 5. Synaptic scaffolding proteins. Scaffolding proteins scaffold numerous proteins to 
complexes and link these complexes to the cytoskeleton. In colour are the proteins linked to ASD 
and in grey their cytoplasmic partners. 
Figure 6. RhoGTPases regulation. GTPase-activating proteins (GAP) and guanine-exchange 
factors (GEF) play a key role in modulating the activity of RhoGTPases, central regulators of 
intracellular actin dynamics. In colour are the proteins linked to ASD and in grey their 
cytoplasmic partners. 
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Highlights 
 The autistic symptoms can be rescued by manipulating actin regulators in Shank3 or 
Fmr1-deficient mice. 
 Many actin regulators associated with ASDs have a role in the regulation of synaptic 
structure and/or function 
 Rho signaling plays a central role in ASD pathology 
 Dysfunction of the actin cytoskeleton at excitatory spine synapses is likely to be a 
molecular pathology that is shared across different neurodevelopmental and psychiatric 
disorders. 
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